Top MarketRank™ StocksTop MarketRank™NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $108.79 +2.34 (+2.20%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$106.77▼$108.8650-Day Range$100.57▼$116.3752-Week Range$99.06▼$137.38Volume654,261 shsAverage Volume688,344 shsMarket Capitalization$6.72 billionP/E Ratio22.43Dividend YieldN/APrice Target$173.07 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Jazz Pharmaceuticals alerts: Email Address Jazz Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside59.1% Upside$173.07 Price TargetShort InterestHealthy3.17% of Float Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment0.51Based on 19 Articles This WeekInsider TradingSelling Shares$152,703 Sold Last QuarterProj. Earnings Growth15.78%From $16.03 to $18.56 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.99 out of 5 starsMedical Sector1st out of 922 stocksPharmaceutical Preparations Industry1st out of 428 stocks 4.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 11 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.17% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 7.35%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 2.5 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Jazz Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for JAZZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $152,703.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 15.78% in the coming year, from $16.03 to $18.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 22.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 118.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 22.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.04.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.31. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used by EVERY single AI company on the planet... AMD, NVIDIA, META... none of these companies could exist without this firm.Click here for the ticker >>> About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Stock News HeadlinesSeptember 12 at 7:25 AM | insidertrades.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) SVP Mary Elizabeth Henderson Sells 1,410 SharesSeptember 13 at 9:58 PM | investing.comJazz Pharmaceuticals executive sells over $150k in company stockSeptember 14, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.September 12 at 3:09 AM | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Needham & Company LLCSeptember 11 at 10:40 AM | markets.businessinsider.comJazz Pharmaceuticals (JAZZ) Receives a Buy from Stifel NicolausSeptember 10, 2024 | markets.businessinsider.comNeedham Remains a Buy on Jazz Pharmaceuticals (JAZZ)September 10, 2024 | markets.businessinsider.comJefferies Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)September 10, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 14, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.September 9, 2024 | prnewswire.comJazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024September 5, 2024 | markets.businessinsider.comAnalyzing Jazz Pharmaceuticals: A Hold Rating Amidst Oncology and Sleep Disorder Market DynamicsSeptember 5, 2024 | bizjournals.comJazz Pharmaceuticals set to raise as much as $1 billion from private notes offeringSeptember 5, 2024 | finance.yahoo.comJazz Pharmaceuticals plc (JAZZ): Among the Best Mid-Cap Healthcare Stocks To Buy NowSeptember 5, 2024 | prnewswire.comJazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024September 4, 2024 | markets.businessinsider.comJazz Pharmaceuticals Announces Pricing Of Private Offering Of Senior NotesSeptember 4, 2024 | prnewswire.comJazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share RepurchasesSeptember 3, 2024 | finance.yahoo.comPrimrose Bio and ExPLoRNA Therapeutics Announce Strategic Partnership to Advance mRNA MedicinesSeptember 3, 2024 | nasdaq.comJazz Announces Private Offering Of $850 Mln Senior NotesSee More Headlines Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today9/14/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$173.07 High Stock Price Target$230.00 Low Stock Price Target$113.00 Potential Upside/Downside+59.1%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)$4.85 Trailing P/E Ratio22.43 Forward P/E Ratio6.79 P/E Growth1.31Net Income$414.83 million Net Margins10.10% Pretax Margin7.61% Return on Equity28.65% Return on Assets9.29% Debt Debt-to-Equity Ratio1.36 Current Ratio2.37 Quick Ratio2.02 Sales & Book Value Annual Sales$3.83 billion Price / Sales1.75 Cash Flow$28.78 per share Price / Cash Flow3.78 Book Value$59.36 per share Price / Book1.83Miscellaneous Outstanding Shares61,750,000Free Float60,413,000Market Cap$6.72 billion OptionableOptionable Beta0.57 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Bruce C. Cozadd (Age 60)Co-Founder, Chairman & CEO Comp: $2.44MMs. Heidi Manna (Age 52)Executive VP & Chief People Officer Dr. Jed Black M.D.Senior Vice President of Sleep & CNS MedicineMs. Samantha Pearce (Age 58)Senior Vice President of Europe & International Mr. John MillerSenior Vice President of Corporate StrategyMs. Aislinn DoodyCompany SecretaryDr. Katherine A. LittrellVice President of Investor RelationsMr. Joshua R. Steinerman M.D.Vice President of NeuropsychiatryMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXACADIA PharmaceuticalsNASDAQ:ACADArrowhead PharmaceuticalsNASDAQ:ARWRBausch Health CompaniesNYSE:BHCMyoKardiaNASDAQ:MYOKView All CompetitorsInsiders & InstitutionsMary Elizabeth HendersonSold 1,410 sharesTotal: $152,703.00 ($108.30/share)Sanctuary Advisors LLCBought 1,950 shares on 9/5/2024Ownership: 0.003%Teachers Retirement System of The State of KentuckySold 54,000 shares on 8/26/2024Ownership: 0.170%Truist Financial CorpSold 4,577 shares on 8/21/2024Ownership: 0.054%Point72 Asset Management L.P.Bought 182,915 shares on 8/19/2024Ownership: 0.289%View All Insider TransactionsView All Institutional Transactions JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $123.00 at the start of the year. Since then, JAZZ stock has decreased by 11.6% and is now trading at $108.79. View the best growth stocks for 2024 here. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released its earnings results on Wednesday, July, 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.87. The specialty pharmaceutical company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a trailing twelve-month return on equity of 28.65% and a net margin of 10.10%. Does Jazz Pharmaceuticals have any subsidiaries? Jazz Pharmaceuticals subsidiaries include these companies: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Top institutional shareholders of Jazz Pharmaceuticals include LSV Asset Management (3.93%), Pacer Advisors Inc. (2.89%), Baupost Group LLC MA (2.02%) and Dimensional Fund Advisors LP (1.94%). Insiders that own company stock include Bruce C Cozadd, Neena M Patil, Robert Iannone, Renee D Gala, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Christopher J Tovey, Mary Elizabeth Henderson, Peter Gray, Samantha Pearce, Rick E Winningham, Anne Oriordan, Mark Douglas Smith, Patricia Carr and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX) and Tesla (TSLA). This page (NASDAQ:JAZZ) was last updated on 9/14/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains...Behind the Markets | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
